Biocept Inc (BIOC) is down -7.36% today. No major news has been announced by the company except it will be relocating its corporate offices and CLIA-certified laboratory to San Diego. Key valuation metrics show the stock to be slightly overvalued at its current price as investors need to be wary since the company is consistently reporting negative earnings.
The commonly used price to book ratio shows a unfavorable value with BIOC’s current price as the 2.92 P/B ratio is above the fair value ratio of 1. Usually anything above a 3 is considered overvalued and Biocept Inc is just below that.
BIOC’s price to sales ratio also isn’t the best at a 2.84 P/S ratio which is higher than the accepted fair value between 1 and 2. Generally anything over 4 is overvalued so paying $2.84 for every $1 of the company’s sales is not the worst value for this company but not great either.
These valuation metrics paint a mixed picture for BIOC at its current price due to below average sales and book value. The company is growing but still in deep negative EPS territory any investor so should be cautious. Biocept is growing though as their 2019 EPS of -$1.22 was significantly up from its 2018 EPS of -$9.01 and its 2017 EPS of -$23.58. The ratios are not the best for this stock but its growth rate may just make it a worthwhile investment.
Biocept Inc (BIOC) stock is down -36.27% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives BIOC stock a score of 83 out of a possible 100.
That score is mainly influenced by a long-term technical score of 96. BIOC’s score also includes a fundamental score of 88. In addition to the average rating from Wall Street analysts, BIOC stock has a mean target price of 1.53. This means analysts expect the stock to increase 135.38% over the next 12 months. The short-term technical score for BIOC is 64.
What’s Happening with BIOC Stock Today
Biocept Inc (BIOC) stock has fallen -7.36% while the S&P 500 has gained 2.63% as of 10:11 AM on Tuesday, Jun 16. BIOC is down -$0.05 from the previous closing price of $0.70 on volume of 11,532,904 shares. Over the past year the S&P 500 is up 8.91% while BIOC is down -36.27%. BIOC lost -$0.93 per share in the over the last 12 months.
